← All trials
NCT03577899
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2018
- Primary completion
- Oct 20, 2020
- Completion date
- Jan 29, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 1140
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chengdu Kanghong Biotech Co.,Ltd.Lead sponsor
- Chengdu Kanghong Biotech Co.,Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.